| 000 | 01599 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515174213.0 | ||
| 264 | 0 | _c20110505 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1873-2496 | ||
| 024 | 7 |
_a10.1016/j.urolonc.2009.03.024 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLangenhuijsen, Johan F | |
| 245 | 0 | 0 |
_aNeoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. _h[electronic resource] |
| 260 |
_bUrologic oncology _c |
||
| 300 |
_a52-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aBuserelin _xtherapeutic use |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFertility Agents, Female _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazolidines _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoadjuvant Therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _avan Lin, Emile N | |
| 700 | 1 | _aHoffmann, Aswin L | |
| 700 | 1 | _aSpitters-Post, Ilse | |
| 700 | 1 | _aAlfred Witjes, J | |
| 700 | 1 | _aKaanders, Johannes H | |
| 700 | 1 | _aMulders, Peter F | |
| 773 | 0 |
_tUrologic oncology _gvol. 29 _gno. 1 _gp. 52-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urolonc.2009.03.024 _zAvailable from publisher's website |
| 999 |
_c18943216 _d18943216 |
||